News | October 27, 2025
Zydus receives approval from Health Canada for Mesalamine suppositories
Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis
Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis
Dr Reddys Laboratories has reported total income of Rs. 8,805.1 crore during the period ended September 30, 2025
Telangana aims to increase the value of the Life Sciences economy from US$ 80 billion to US$ 250 billion by 2030
With milestone-linked funding of Rs. 5–25 crore per project (and up to Rs. 50 crore in exceptional cases), the Mission will support projects that bring impactful MedTech solutions to market
Laurus Labs has reported total income of Rs. 1,680.43 crore during the period ended September 30, 2025
_256_384.jpg)
Tirzepatide is a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
The product is indicated for the chronic management of patients with Urea Cycle Disorders
Yesintek and Yesintek I.V. are approved for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients
Glenmark’s Ropivacaine Hydrochloride Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug Naropin Injection of Fresenius Kabi USA
The submissions are supported by data from the Phase 3 KEYNOTE-905 trial
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
